Risperidone Tablet, Orally Disintegrating
NDC Package 69339-182-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Risperidone tablets is risperidone is used to treat certain mental/mood disorders (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder). This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Natco Pharma Usa Llc, this product is identified by NDC 69339-182 and is authorized under FDA application ANDA091537.

Identification & Billing

NDC Package Code
69339-182-03
Package Description
30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
Product Code
11-Digit Billing Format
69339018203
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Risperidone
Non-Proprietary Name
Risperidone
Substance Name
Risperidone
Dosage Form
Tablet, Orally Disintegrating - A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Risperidone is used to treat certain mental/mood disorders (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder). This medication can help you to think clearly and take part in everyday life. Risperidone belongs to a class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain.

Regulatory & Marketing

Labeler Name
Natco Pharma Usa Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA091537
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-14-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69339-182-03 identifies a specific commercial package of 30 tablet, orally disintegrating in 1 bottle of Risperidone, a human prescription drug labeled by Natco Pharma Usa Llc. This tablet, orally disintegrating is formulated for oral use and contains risperidone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Natco Pharma Usa Llc on October 14, 2023. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Risperidone is used to treat certain mental/mood disorders (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder). This medication can help you to think clearly and take part in everyday life. Risperidone belongs to a class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain.

How is this Natco Pharma Usa Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69339018203. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69339-182-03
11-Digit CMS (5-4-2)
69339-0182-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.